137 pharmaceutical companies released their transcripts for the first half of the year!

With substantial growth in performance, Lanfan Medical said that on the one hand, the new crown epidemic in the first half of the year was still relatively severe overseas, and the demand for protective glove products continued to grow.
Product prices and sales volume increased significantly compared with the same period last year, which had a positive impact on the company's performance
.
On the other hand, according to the "Earnings Forecast Compensation Agreement on CBCardioHoldingsIILimited" signed with the performance commitment Fang Lanfan Investment, LiBingYung, ThomasKennethGraham, and WangDan during the company's major asset reorganization, and the "Earning Forecast on CBCardioHoldingsVLimited" signed with Beijing Xinyu Investment Center (Limited Partnership) Compensation Agreement", the target company CBCardioHoldingsIILimited did not fulfill its 2020 annual performance commitments.
The company held the 15th meeting of the Fifth Board of Directors and the 14th Meeting of the Fifth Board of Supervisors on May 17, 2021, on June 8, 2021.
The 2020 Annual General Meeting of Shareholders was convened on March 31 to deliberate and approve the "Proposal on the Performance Compensation Plan for Major Asset Restructuring Subjects".
The total amount of performance compensation and compensation shares equivalent to approximately 1.
095 billion yuan was implemented in June
.

On July 27, Bluesail Medical issued an announcement that it plans to establish a wholly-owned subsidiary, Shanghai Bluesail, in Shanghai with its own funds of 500 million yuan, which will mainly host the global innovative R&D headquarters, investment incubation platform, high-end medical device production, and global business headquarters.
Construction
.
Bluesail Medical said that this investment is conducive to increasing research and development efforts, further enriching product structure and business levels, promoting the introduction of industrial resources, financial resources and human resources into the company, establishing a development platform, and assisting the company's strategic landing and new business expansion
.

Qizheng, Taiji.
.
.
50 companies doubled their net profits, 15 companies turned losses

According to statistics, the net profits of 50 companies including Qizheng Tibetan Medicine, Kelun Pharmaceutical, Taiji Group, and Huaren Pharmaceutical have doubled.
Among them, 6 companies have increased by more than 1,000%, and Hotview Bio has increased by 800 times.
"Pre-increasing king", net profit soared from nearly 2 million yuan to 1.
6 billion yuan; 15 companies including Harbin Pharmaceutical Co.
, Ltd.
, Donge Ejiao, Tonghua Jinma and other companies turned losses into profits, while Kangsino made a "big turnaround" from a loss of 100 million yuan to a profit.
Over 1 billion yuan
.

Qizheng Tibetan Medicine

Revenue: 781 million yuan, a year-on-year increase: 27.
69%

Net profit: 989 million yuan, a year-on-year increase: 346.
92%

Qizheng Tibetan Medicine said that in the first half of the year, the company achieved operating income of 781 million yuan, a year-on-year increase of 27.
69%, of which the pharmaceutical business increased by 27.
21% year-on-year
.
Net profit was 989 million yuan, an increase of 346.
92% year-on-year.
The main reason was that after Baiyang Pharmaceutical went public, the M&A fund Tibet Qunying Investment Center (Limited Partnership), which the company participated in, confirmed the increase in gains and losses from changes in fair value at open market prices.
Investment is accounted for in accordance with the equity method, and the increase in investment income is recognized.
This matter is non-recurring gains and losses
.

Huaren Pharmaceutical

Net profit: 68 million to 80 million yuan

Year-on-year growth: 93.
66%~127.
83%

Huaren Pharmaceutical said that due to the epidemic in the first half of 2020, the company's normal production and operation will be affected to a certain extent, and the sales of infusion products will drop to a certain extent
.
In the first half of 2021, with the effective control of the domestic epidemic situation and the gradual recovery of the company’s various businesses, the company will continue to improve sales channels, open up incremental markets, strengthen market access, and actively embrace the national policy of centralized procurement of infusion products.
Sales have increased compared to the same period last year
.
The company actively promoted the layout of the entire pharmaceutical and health industry chain, and further broadened the company's pharmaceutical commercial business scope.
The pharmaceutical commercial segment business has grown steadily, contributing part of the profit
.
In addition, in 2020, the company acquired 100% equity of Guangxi Yuyuan Pharmaceutical and Pubei Xinke Pharmaceutical Packaging, which will be included in the consolidated statement from November 2020, contributing part of the profit in the first half of the year
.

A few days ago, Huaren Pharmaceutical issued an announcement stating that Qujiang Huaren, a wholly-owned subsidiary of the company, used its own funds of 800 million yuan to acquire 100% equity of Hengjuxing Pharmaceutical held by the counterparty, and indirectly holds 100% equity of Stellar Pharmaceuticals
.
Huaren Pharmaceuticals stated that through this acquisition, the company can quickly obtain over-reviewed varieties, collectively-sourced varieties and under-research varieties, further enrich the company's drug varieties and R&D pipelines, and promote the company's innovation, upgrading and rapid development in the construction of R&D platforms.
Empower the company to achieve rapid and stable development
.
After the completion of the acquisition, the company will actively carry out channel integration, production, and team integration of the company's existing varieties of products such as Stellar Pharmaceutical Respiratory Medicine and fine hemp, so as to realize resource sharing, give full play to the synergistic effect, and realize the rapid increase of existing varieties
.

Source: Oriental Fortune.
com, Announcement of Listed Companies

Please correct me if there are any errors or omissions
.